Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients
There are over 10 million hepatitis C virus (HCV)-infected patients in Pakistan. For these patients, a combination of interferon with ribavirin is the most economical and easily available treatment. Single-nucleotide polymorphisms in interleukin genes have been reported to be associated with the pat...
Gespeichert in:
| Veröffentlicht in: | Archives of virology 2018-04, Vol.163 (4), p.997-1008 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1008 |
|---|---|
| container_issue | 4 |
| container_start_page | 997 |
| container_title | Archives of virology |
| container_volume | 163 |
| creator | Naeemi, Humaira Aslam, Rabia Raza, Syed Mohsin Shahzad, Muhammad Aiman Naz, Shagufta Manzoor, Sobia Khaliq, Saba |
| description | There are over 10 million hepatitis C virus (HCV)-infected patients in Pakistan. For these patients, a combination of interferon with ribavirin is the most economical and easily available treatment. Single-nucleotide polymorphisms in interleukin genes have been reported to be associated with the pathogenesis and clearance of HCV, and sustained virologic response (SVR). An
interleukin 28B
(
IL28B
) gene polymorphism has been shown to modify treatment outcomes, but the effects of
interleukin 10
(
IL10
) polymorphisms have not been previously assessed in the Pakistani population. The present study was conducted with 302 subjects categorized into two groups: 100 healthy volunteers (Group I) and 202 patients with chronic HCV (Group II). Patients within Group II were further divided into two subgroups according to therapeutic response: SVR (responders = 132) and NR (non-responders/relapsers = 70).
IL28B
(rs8099917, rs12979860) and
IL10
(rs1800872, rs1800871, rs1800896) gene polymorphisms were studied in all subjects. A significant difference in the distribution of
IL28B
rs12979860C/T genotypes between the two groups (
p |
| doi_str_mv | 10.1007/s00705-018-3711-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1992870462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1992870462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-fbcf3f465bbedfe42d6a45d71e70b9b1d7d740e72d57ce56b753ebb72bd5f4c73</originalsourceid><addsrcrecordid>eNp1kL1OHDEUha0oKGxIHiBNZCn1hOufGc-UYfMD0kpQAK1lj-8QE8YebG-xRd4dr5ZENDS2df2dc6WPkE8MvjIAdZrrAW0DrG-EYqwRb8iKScGbXg39W7ICAbLpO-iPyfuc7wHqQLTvyDEfhIQeuhX5-93nkrzdFh8DjRO92PD-jJrg6osBXeLDbo5p-e3znKnJ9A4DFj_SJaHzY4kp71MloSkzhkIT5iWGjNQHemX-1HYTPD1f3-6TsewWpIIupvgK5w_kaDIPGT8-3yfk5ueP6_V5s7n8dbH-tmlGoXhpJjtOYpJday26CSV3nZGtUwwV2MEyp5ySgIq7Vo3Ydla1Aq1V3Lp2kqMSJ-TLoXdJ8XGLuej7uE2hrtRsGHivQHa8UuxAjSnmnHDSS_KzSTvNQO-F64NwXYXrvXAtaubzc_PWzuj-J_4ZrgA_ALl-hTtML1a_2voE-OKMvg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1992870462</pqid></control><display><type>article</type><title>Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Naeemi, Humaira ; Aslam, Rabia ; Raza, Syed Mohsin ; Shahzad, Muhammad Aiman ; Naz, Shagufta ; Manzoor, Sobia ; Khaliq, Saba</creator><creatorcontrib>Naeemi, Humaira ; Aslam, Rabia ; Raza, Syed Mohsin ; Shahzad, Muhammad Aiman ; Naz, Shagufta ; Manzoor, Sobia ; Khaliq, Saba</creatorcontrib><description>There are over 10 million hepatitis C virus (HCV)-infected patients in Pakistan. For these patients, a combination of interferon with ribavirin is the most economical and easily available treatment. Single-nucleotide polymorphisms in interleukin genes have been reported to be associated with the pathogenesis and clearance of HCV, and sustained virologic response (SVR). An
interleukin 28B
(
IL28B
) gene polymorphism has been shown to modify treatment outcomes, but the effects of
interleukin 10
(
IL10
) polymorphisms have not been previously assessed in the Pakistani population. The present study was conducted with 302 subjects categorized into two groups: 100 healthy volunteers (Group I) and 202 patients with chronic HCV (Group II). Patients within Group II were further divided into two subgroups according to therapeutic response: SVR (responders = 132) and NR (non-responders/relapsers = 70).
IL28B
(rs8099917, rs12979860) and
IL10
(rs1800872, rs1800871, rs1800896) gene polymorphisms were studied in all subjects. A significant difference in the distribution of
IL28B
rs12979860C/T genotypes between the two groups (
p
<0.05) was observed, while of the three
IL10
polymorphisms, a significant difference was only shown for rs1800896 A/G. Haplotype analysis (
IL28B
and
IL10
) showed a significant association of TTGTC and TTGTA when comparing the groups. There was a strong association of the favorable alleles rs8099917T and rs12979860C in the SVR group as compared with the NR group (
p
<0.05), and rs1800896 also showed an association with the SVR group as compared to the NR group (
p
<0.004). Haplotype analysis showed significant associations when comparing the SVR and NR subgroups, i.e. TCATC (
p
=0.009), TTGTA (
p
=0.005), TCATA (
p
<0.0005), TCACA (
p
=0.002), GTGCC (
p
=0.002) and TCGTC (
p
=0.005).
IL28B
(rs8099917 and rs12979860) and
IL10
(rs1800896) polymorphisms alone, or in combination, are good predictors of therapeutic response in HCV-3a patients.</description><identifier>ISSN: 0304-8608</identifier><identifier>EISSN: 1432-8798</identifier><identifier>DOI: 10.1007/s00705-018-3711-3</identifier><identifier>PMID: 29340806</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Adult ; Alleles ; Antiviral Agents - therapeutic use ; Biomarkers - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Case-Control Studies ; Cytokines ; Drug Therapy, Combination ; Female ; Gene Expression ; Gene Frequency ; Gene polymorphism ; Genotypes ; Haplotypes ; Hepacivirus - classification ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepacivirus - isolation & purification ; Hepatitis C ; Hepatitis C, Chronic - diagnosis ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - genetics ; Hepatitis C, Chronic - immunology ; Humans ; Infectious Diseases ; Interferon ; Interferon-alpha - therapeutic use ; Interferons ; Interleukin 1 ; Interleukin 10 ; Interleukin-10 - genetics ; Interleukin-10 - immunology ; Interleukins - genetics ; Interleukins - immunology ; Male ; Medical Microbiology ; Middle Aged ; Original Article ; Pakistan ; Patients ; Polyethylene Glycols - therapeutic use ; Polymorphism ; Polymorphism, Single Nucleotide ; Population studies ; Prognosis ; Recombinant Proteins - therapeutic use ; Ribavirin ; Ribavirin - therapeutic use ; Single-nucleotide polymorphism ; Virology</subject><ispartof>Archives of virology, 2018-04, Vol.163 (4), p.997-1008</ispartof><rights>Springer-Verlag GmbH Austria, part of Springer Nature 2018</rights><rights>Archives of Virology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-fbcf3f465bbedfe42d6a45d71e70b9b1d7d740e72d57ce56b753ebb72bd5f4c73</citedby><cites>FETCH-LOGICAL-c372t-fbcf3f465bbedfe42d6a45d71e70b9b1d7d740e72d57ce56b753ebb72bd5f4c73</cites><orcidid>0000-0002-0345-7394</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00705-018-3711-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00705-018-3711-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29340806$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naeemi, Humaira</creatorcontrib><creatorcontrib>Aslam, Rabia</creatorcontrib><creatorcontrib>Raza, Syed Mohsin</creatorcontrib><creatorcontrib>Shahzad, Muhammad Aiman</creatorcontrib><creatorcontrib>Naz, Shagufta</creatorcontrib><creatorcontrib>Manzoor, Sobia</creatorcontrib><creatorcontrib>Khaliq, Saba</creatorcontrib><title>Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients</title><title>Archives of virology</title><addtitle>Arch Virol</addtitle><addtitle>Arch Virol</addtitle><description>There are over 10 million hepatitis C virus (HCV)-infected patients in Pakistan. For these patients, a combination of interferon with ribavirin is the most economical and easily available treatment. Single-nucleotide polymorphisms in interleukin genes have been reported to be associated with the pathogenesis and clearance of HCV, and sustained virologic response (SVR). An
interleukin 28B
(
IL28B
) gene polymorphism has been shown to modify treatment outcomes, but the effects of
interleukin 10
(
IL10
) polymorphisms have not been previously assessed in the Pakistani population. The present study was conducted with 302 subjects categorized into two groups: 100 healthy volunteers (Group I) and 202 patients with chronic HCV (Group II). Patients within Group II were further divided into two subgroups according to therapeutic response: SVR (responders = 132) and NR (non-responders/relapsers = 70).
IL28B
(rs8099917, rs12979860) and
IL10
(rs1800872, rs1800871, rs1800896) gene polymorphisms were studied in all subjects. A significant difference in the distribution of
IL28B
rs12979860C/T genotypes between the two groups (
p
<0.05) was observed, while of the three
IL10
polymorphisms, a significant difference was only shown for rs1800896 A/G. Haplotype analysis (
IL28B
and
IL10
) showed a significant association of TTGTC and TTGTA when comparing the groups. There was a strong association of the favorable alleles rs8099917T and rs12979860C in the SVR group as compared with the NR group (
p
<0.05), and rs1800896 also showed an association with the SVR group as compared to the NR group (
p
<0.004). Haplotype analysis showed significant associations when comparing the SVR and NR subgroups, i.e. TCATC (
p
=0.009), TTGTA (
p
=0.005), TCATA (
p
<0.0005), TCACA (
p
=0.002), GTGCC (
p
=0.002) and TCGTC (
p
=0.005).
IL28B
(rs8099917 and rs12979860) and
IL10
(rs1800896) polymorphisms alone, or in combination, are good predictors of therapeutic response in HCV-3a patients.</description><subject>Adult</subject><subject>Alleles</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biomarkers - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Case-Control Studies</subject><subject>Cytokines</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Gene Frequency</subject><subject>Gene polymorphism</subject><subject>Genotypes</subject><subject>Haplotypes</subject><subject>Hepacivirus - classification</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - diagnosis</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - genetics</subject><subject>Hepatitis C, Chronic - immunology</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferons</subject><subject>Interleukin 1</subject><subject>Interleukin 10</subject><subject>Interleukin-10 - genetics</subject><subject>Interleukin-10 - immunology</subject><subject>Interleukins - genetics</subject><subject>Interleukins - immunology</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Pakistan</subject><subject>Patients</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Polymorphism</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Population studies</subject><subject>Prognosis</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Single-nucleotide polymorphism</subject><subject>Virology</subject><issn>0304-8608</issn><issn>1432-8798</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kL1OHDEUha0oKGxIHiBNZCn1hOufGc-UYfMD0kpQAK1lj-8QE8YebG-xRd4dr5ZENDS2df2dc6WPkE8MvjIAdZrrAW0DrG-EYqwRb8iKScGbXg39W7ICAbLpO-iPyfuc7wHqQLTvyDEfhIQeuhX5-93nkrzdFh8DjRO92PD-jJrg6osBXeLDbo5p-e3znKnJ9A4DFj_SJaHzY4kp71MloSkzhkIT5iWGjNQHemX-1HYTPD1f3-6TsewWpIIupvgK5w_kaDIPGT8-3yfk5ueP6_V5s7n8dbH-tmlGoXhpJjtOYpJday26CSV3nZGtUwwV2MEyp5ySgIq7Vo3Ydla1Aq1V3Lp2kqMSJ-TLoXdJ8XGLuej7uE2hrtRsGHivQHa8UuxAjSnmnHDSS_KzSTvNQO-F64NwXYXrvXAtaubzc_PWzuj-J_4ZrgA_ALl-hTtML1a_2voE-OKMvg</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Naeemi, Humaira</creator><creator>Aslam, Rabia</creator><creator>Raza, Syed Mohsin</creator><creator>Shahzad, Muhammad Aiman</creator><creator>Naz, Shagufta</creator><creator>Manzoor, Sobia</creator><creator>Khaliq, Saba</creator><general>Springer Vienna</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0002-0345-7394</orcidid></search><sort><creationdate>20180401</creationdate><title>Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients</title><author>Naeemi, Humaira ; Aslam, Rabia ; Raza, Syed Mohsin ; Shahzad, Muhammad Aiman ; Naz, Shagufta ; Manzoor, Sobia ; Khaliq, Saba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-fbcf3f465bbedfe42d6a45d71e70b9b1d7d740e72d57ce56b753ebb72bd5f4c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Alleles</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biomarkers - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Case-Control Studies</topic><topic>Cytokines</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Gene Frequency</topic><topic>Gene polymorphism</topic><topic>Genotypes</topic><topic>Haplotypes</topic><topic>Hepacivirus - classification</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - diagnosis</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - genetics</topic><topic>Hepatitis C, Chronic - immunology</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferons</topic><topic>Interleukin 1</topic><topic>Interleukin 10</topic><topic>Interleukin-10 - genetics</topic><topic>Interleukin-10 - immunology</topic><topic>Interleukins - genetics</topic><topic>Interleukins - immunology</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Pakistan</topic><topic>Patients</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Polymorphism</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Population studies</topic><topic>Prognosis</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Single-nucleotide polymorphism</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naeemi, Humaira</creatorcontrib><creatorcontrib>Aslam, Rabia</creatorcontrib><creatorcontrib>Raza, Syed Mohsin</creatorcontrib><creatorcontrib>Shahzad, Muhammad Aiman</creatorcontrib><creatorcontrib>Naz, Shagufta</creatorcontrib><creatorcontrib>Manzoor, Sobia</creatorcontrib><creatorcontrib>Khaliq, Saba</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><jtitle>Archives of virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naeemi, Humaira</au><au>Aslam, Rabia</au><au>Raza, Syed Mohsin</au><au>Shahzad, Muhammad Aiman</au><au>Naz, Shagufta</au><au>Manzoor, Sobia</au><au>Khaliq, Saba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients</atitle><jtitle>Archives of virology</jtitle><stitle>Arch Virol</stitle><addtitle>Arch Virol</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>163</volume><issue>4</issue><spage>997</spage><epage>1008</epage><pages>997-1008</pages><issn>0304-8608</issn><eissn>1432-8798</eissn><abstract>There are over 10 million hepatitis C virus (HCV)-infected patients in Pakistan. For these patients, a combination of interferon with ribavirin is the most economical and easily available treatment. Single-nucleotide polymorphisms in interleukin genes have been reported to be associated with the pathogenesis and clearance of HCV, and sustained virologic response (SVR). An
interleukin 28B
(
IL28B
) gene polymorphism has been shown to modify treatment outcomes, but the effects of
interleukin 10
(
IL10
) polymorphisms have not been previously assessed in the Pakistani population. The present study was conducted with 302 subjects categorized into two groups: 100 healthy volunteers (Group I) and 202 patients with chronic HCV (Group II). Patients within Group II were further divided into two subgroups according to therapeutic response: SVR (responders = 132) and NR (non-responders/relapsers = 70).
IL28B
(rs8099917, rs12979860) and
IL10
(rs1800872, rs1800871, rs1800896) gene polymorphisms were studied in all subjects. A significant difference in the distribution of
IL28B
rs12979860C/T genotypes between the two groups (
p
<0.05) was observed, while of the three
IL10
polymorphisms, a significant difference was only shown for rs1800896 A/G. Haplotype analysis (
IL28B
and
IL10
) showed a significant association of TTGTC and TTGTA when comparing the groups. There was a strong association of the favorable alleles rs8099917T and rs12979860C in the SVR group as compared with the NR group (
p
<0.05), and rs1800896 also showed an association with the SVR group as compared to the NR group (
p
<0.004). Haplotype analysis showed significant associations when comparing the SVR and NR subgroups, i.e. TCATC (
p
=0.009), TTGTA (
p
=0.005), TCATA (
p
<0.0005), TCACA (
p
=0.002), GTGCC (
p
=0.002) and TCGTC (
p
=0.005).
IL28B
(rs8099917 and rs12979860) and
IL10
(rs1800896) polymorphisms alone, or in combination, are good predictors of therapeutic response in HCV-3a patients.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>29340806</pmid><doi>10.1007/s00705-018-3711-3</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-0345-7394</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-8608 |
| ispartof | Archives of virology, 2018-04, Vol.163 (4), p.997-1008 |
| issn | 0304-8608 1432-8798 |
| language | eng |
| recordid | cdi_proquest_journals_1992870462 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Alleles Antiviral Agents - therapeutic use Biomarkers - metabolism Biomedical and Life Sciences Biomedicine Case-Control Studies Cytokines Drug Therapy, Combination Female Gene Expression Gene Frequency Gene polymorphism Genotypes Haplotypes Hepacivirus - classification Hepacivirus - drug effects Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis C Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Hepatitis C, Chronic - immunology Humans Infectious Diseases Interferon Interferon-alpha - therapeutic use Interferons Interleukin 1 Interleukin 10 Interleukin-10 - genetics Interleukin-10 - immunology Interleukins - genetics Interleukins - immunology Male Medical Microbiology Middle Aged Original Article Pakistan Patients Polyethylene Glycols - therapeutic use Polymorphism Polymorphism, Single Nucleotide Population studies Prognosis Recombinant Proteins - therapeutic use Ribavirin Ribavirin - therapeutic use Single-nucleotide polymorphism Virology |
| title | Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T07%3A06%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distribution%20of%20IL28B%20and%20IL10%20polymorphisms%20as%20genetic%20predictors%20of%20treatment%20response%20in%20Pakistani%20HCV%20genotype%203%20patients&rft.jtitle=Archives%20of%20virology&rft.au=Naeemi,%20Humaira&rft.date=2018-04-01&rft.volume=163&rft.issue=4&rft.spage=997&rft.epage=1008&rft.pages=997-1008&rft.issn=0304-8608&rft.eissn=1432-8798&rft_id=info:doi/10.1007/s00705-018-3711-3&rft_dat=%3Cproquest_cross%3E1992870462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1992870462&rft_id=info:pmid/29340806&rfr_iscdi=true |